2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
09:30 a.m. - 11:00 a.m.
MCCNO - Great Hall AD
Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Apoptosis, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Research, Fundamental Science, AML, Translational Research
PAPER

554 Targeting of the leukemia-restricted antigen CLEC2A overcomes a fundamental barrier to safe and potent cellular therapy for acute myeloid leukemia

Danielle C. Kirkey, MD, Grace Hawkins2, Melia Blankenfeld, BS3, Isabel Lira, BS4, Nika Panahi5, Bruce Liu6, Rhonda E. Ries, MA7, Jack H. Peplinski, MSc8, Benjamin J. Huang, MD9, Scott N Furlan, MD10, Biagio De Angelis, PhD11, Concetta Quintarelli, PhD12, Corinne Summers, MD13, Katherine Tarlock I, MD14, Franco Locatelli, MD PhD15, Wei Li, PhD16, Soheil Meshinchi, MD, PhD17
1 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States
2 Fred Hutchinson Cancer Center, Seattle, Washington, United States
3 Fred Hutchinson Cancer Center, Seattle, Washington, United States
4 Fred Hutchinson Cancer Center, Seattle, Washington, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Fred Hutchinson Cancer Center, Seattle, Washington, United States
7 Fred Hutchinson Cancer Center, Seattle, Washington, United States
8 Fred Hutchinson Cancer Center, Seattle, Washington, United States
9 University of California San Francisco, San Francisco, California, United States
10 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States
11 Bambino Gesù Pediatric Hospital, Roma, Italy
12 Bambino Gesù Pediatric Hospital, Roma, Italy
13 Seattle Children's Hospital, Seattle, Washington, United States
14 Seattle Children's Hospital, Seattle, Washington, United States
15 Bambino Gesù Pediatric Hospital, Roma, Italy
16 University Of Pittsburgh, Pittsburgh, Pennsylvania, United States
17 Fred Hutchinson Cancer Center, Seattle, Washington, United States, Seattle Children's Hospital, Seattle, Washington, United States

Despite intensive chemotherapy and allogeneic stem cell transplant, many patients with acute myeloid leukemia (AML) relapse or develop refractory disease associated with poor outcomes. For decades, AML immunotherapy has assumed that potent antileukemic activity necessarily requires targeting antigens shared with normal hematopoiesis, resulting in unavoidable risk for hematopoietic toxicity. Our work challenges this paradigm. FOLR1 CAR-T therapy has provided the first clinical evidence that AML-restricted targeting can produce meaningful efficacy without hematopoietic toxicity (Tarlock et al; ASH 2026); CLEC2A extends this concept to a second biologically distinct AML subtype with comprehensive preclinical evidence of an exceptionally favorable safety profile presented here. Together, these studies suggest that leukemia-restricted antigen targeting may represent a broadly applicable strategy for AML immunotherapy rather than an isolated observation.

With CLEC2A CAR-T therapy entering first-in-human clinical evaluation, we conducted IND-enabling toxicity assessments. We broadly evaluated target-dependent toxicity in normal tissues with comprehensive tissue cross-reactivity studies using our human CLEC2A 3H10 antibody with no detectable binding across 37 normal tissues from three independent donors. As hematopoietic toxicity has remained a major concern with AML-directed CAR-T therapy, we systematically evaluated direct hematopoietic cytotoxicity, impact on clonogenic capacity and engraftment potential. To evaluate direct hematopoietic toxicity, CD34+ hematopoietic stem/progenitor cells (HSPCs) from three donors were co-cultured with CLEC2A CAR-T, unmodified T cells, or media alone at a 1:1 effector:target cell ratio. Flow cytometry analysis found no HSPC cytotoxicity and no impact on HSPC viability when co-cultured with CLEC2A CAR-T, unmodified T or media alone (p=0.96). Colony-forming assays showed preserved clonogenic capacity, with equivalent numbers of G/M/GM, BFU-E, and GEMM colonies across all treatment groups. To evaluate engraftment potential, HSPCs pre-exposed to CLEC2A CAR-T or unmodified T cells for 24-hours were subsequently transplanted into NSG-SGM3 mice. Bone marrow analysis at 6 weeks post-transplant demonstrated expected and comparable human hematopoietic engraftment with CLEC2A CAR-T compared to unmodified T cells (65% vs. 67%, p=0.89) or untreated CD34+ HSPCs (p=0.38). Lastly, we evaluated potential skin toxicity, where CLEC2A mRNA transcript has been reported (GTEx), though protein expression appears limited. Flow cytometry demonstrated minimal to absent CLEC2A expression on epidermal keratinocytes and dermal fibroblasts. Co-culture with CLEC2A CAR-T cells did not induce cytotoxicity (<1% cell death in epidermal keratinocytes, 2.7% cell death in dermal fibroblasts) and minimal cytokine production was noted, comparable to co-culture with unmodified T cells.

Lastly to extend the preclinical evaluation of CLEC2A CAR-T therapy we assessed anti-leukemic efficacy and survival in a high-risk KMT2A::MLLT4 patient-derived xenograft model. Across independent experiments using T cells from two donors, CLEC2A CAR-T cells (1x107 cells per mouse) eradicated leukemia and significantly prolonged survival compared to unmodified T cell-treated and untreated control mice (median 140 days vs. 40 days vs. 41 days respectively, p<0.0001). Bone marrow aspirates around Day 42 demonstrated complete leukemia clearance in all CLEC2A CAR-T treated mice, whereas all control mice harbored 40–100% AML burden in the bone marrow (p<0.0001).

CLEC2A has emerged as a truly leukemia-specific surface antigen whose selective expression enables potent antileukemic activity, while avoiding target-dependent recognition of normal tissues. The restricted expression of CLEC2A and lack of hematopoietic toxicity provides an ideal targeted therapy for relapsed/refractory CLEC2A+ AML including relapse post-transplant. scRNA sequencing from 2 patients with post-transplant relapse revealed high CLEC2A expression uniquely in the relapsed AML cells without any expression in the healthy donor hematopoietic cells. Together with the emerging clinical experience of FOLR1-directed CAR-T cells, these findings support AML-restricted antigen targeting as a new therapeutic paradigm capable of separating efficacy from hematopoietic toxicity- a central challenge that has limited AML immunotherapy for decades.
Danielle C. Kirkey, MD: No relevant conflicts of interest to declare.